ReachMD CME

ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

  1. 4 dgn geleden

    Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF

    CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice. =

    17 min.

  2. 16 jun

    Unblocking Clinical Inertia: The CMI Era in oHCM Care

    CME credits: 0.75 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/unblocking-clinical-inertia-the-cmi-era-in-ohcm-care/56382/ Did you miss our symposium at ESC HF 2026? It’s not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart failure and how cardiac myosin inhibitors can optimize patient outcomes. Join us and gain valuable tips on applying these insights in practice. For more information please visit the Heart Failure Congress 2026 website. =

    39 min.

  3. 8 mei

    FXIa Remix! Keeping the Flow Without Missing a Beat

    CME credits: 0.50 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/fxia-remix-keeping-the-flow-without-missing-a-beat/54142/ Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasis. The panel reviews pivotal OCEANIC-STROKE results presented at ISC 2026, highlighting a 26% relative risk reduction in ischemic stroke without an observed increase in ISTH major bleeding. They examine outcomes across stroke subtypes and place these results in context with other agents in development, such as milvexian and abelacimab. This conversation considers whether factor XI inhibition may alter long-standing assumptions about the tradeoff between efficacy and safety in secondary stroke prevention. =

    24 min.

  4. 8 mei

    Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors

    CME credits: 0.25 Valid until: 08-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/ This interview-style activity brings together a physician and nurse to explore the scientific rationale and clinical evidence behind subcutaneous (SC) immune checkpoint inhibitors (ICIs) in solid tumors. Through discussion of key clinical trials, they highlight pharmacokinetic equivalence, efficacy, and safety data compared with intravenous delivery. The conversation also offers practical insights for integrating SC ICIs into clinical workflows—including patient selection, administration techniques, and management of immune-related adverse events—while considering potential benefits for patient experience, nursing practice, and healthcare resource use. =

    15 min.

  5. 7 mei

    Brain Metastases Management: From Detection to Multidisciplinary Care

    CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/brain-metastases-management-from-detection-to-multidisciplinary-care/56517/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

    6 min.

  6. 7 mei

    EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions

    CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

    10 min.

  7. 7 mei

    First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases

    CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/first-line-management-of-hrher2-low-breast-cancer-with-brain-metastases/56519/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

    10 min.

  8. 7 mei

    HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era

    CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/her2-breast-cancer-with-brain-metastases-rethinking-first-line-treatment-in-the-adc-era/56518/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

    10 min.
Bekijk alles (405)

Info

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Informatie

  • Maker
    ReachMD
  • Jaren actief
    2015 - 2026
  • Afleveringen
    405
  • Beoordeling
    Veilig
  • Copyright
    © Copyright 2026 ReachMD. All rights reserved.
  • Website van aflevering
    ReachMD CME